Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected…
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the…
OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel…
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE…
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered…
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with…
Science 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA InspectionRESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE…
SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today…
Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary…